Recruiting
Phase 2

FM220

Sponsor:

FlowMedic

Code:

NCT00146666

Conditions

Peripheral Arterial Disease

Intermittent Claudication

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Interventions

Intermittent compression

Study Details

Brief summary:

The purpose of this study is to determine whether 12 weeks of daily home use of the FM220 in the most affected leg of patients with PAD and claudication, will improve peak walking time (PWT) at three months as compared with a non-treated control group.

Conditions

Peripheral Arterial Disease

Intermittent Claudication

Study ID

NCT00146666

Start date

Sep, 2005

Status verified date

Aug, 2009

Completion date

Sep, 2006

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 40+

Healthy Volunteers: Not accepted

Inclusion Criteria(main):

1. Patients aged 40 or more.
2. Peripheral arterial disease as determined by resting ABI<0.90.
3. Reduction in post exercise Ankle Brachial Index (ABI) of > 20% in the symptomatic limb.
4. Stable claudication for the past three months
5. Baseline PWT between 1 and 10 minutes
6. If the patient is under claudication drug therapy (eg. cilostazol and pentoxifvlline) the use and dose of these drugs has been stable for the last 60 days.
7. If the patient is receiving of statin and antiplatelet therapy, the use and dose of these drugs has been stable for the last 60 days.

Exclusion Criteria:

1. Any active pathological heart, muscular, neurological, orthopedic, cognitive or pulmonary disease which might interfere with patient compliance or ability to walk on a treadmill in the opinion of the investigator.
2. Non compressible arteries as defined by ABI>1.1
3. Clinical evidence of acute or subacute superficial or deep venous thrombosis confirmed by continuous-wave Doppler in the affected extremity.
4. Deep venous insufficiency on clinical grounds or by lab measurements.
5. Prior below-knee surgical revascularization procedure within the last 6 months.
6. Significant likelihood of lower extremity arterial revascularization procedure within the next 6 months.
7. Ulcer, cellulitis, skin conditions, or superficial thrombophlebitis in regions covered by the compression device preventing use of the device.
8. Acute pulmonary embolism.
9. Osteomyelitis of the lower extremity.
10. Gangrene of the lower extremity.
11. Acute limb ischemia.
12. Clinical scenarios in which increased venous or lymphatic return is undesirable.
13. Painful calf conditions which would exclude use of the pump.
14. Peripheral neuropathy that, in the opinion of the investigator, would prevent patient from accurately assessing claudication symptoms or identifying Cutaneous comfort of the device Vein ligation.
15. Pulmonary edema.
16. Significant aorto-iliac disease as demonstrated by physical examination or objective testing. Absence of aorto-iliac disease must be documented by segmental testing performed within 90 days of study enrollment.
17. Critical leg ischemia with evidence of rest pain, ischemic ulceration, gangrene.
18. Participation in any clinical trial within the past 30 days.
19. Morbid obesity, defined by BMI>40, weight greater than 300 lbs or leg circumference greater than 19.7 inches.
20. Pregnancy.

Study Design

Enrollment

90 participants

Anticipated

Allocation

Randomized

Intervention Model

Parallel Assignment

Primary purpose

Treatment

Interventions and Outcome Measures

Interventions

Intermittent compression

Primary outcome measure

  • Increase in Peak Walking Time as determined on graded treadmill test at 12 weeks [ Time Frame: undefined ]

Central Contacts and Locations

Central contacts

Locations

Jacksonville Center for Clinical Research

Recruiting

Jacksonville, Florida, United States, 32216

Contacts

Principal Investigator:

Michael Koren, MD

Peripheral Vascular Associates

Recruiting

San Antonio, Texas, United States, 78205

Contacts

Principal Investigator:

Jeffrey M Martinez, MD

More Information

Sponsor

FlowMedic

Last update posted

Dec 17, 2009

Last verified

Aug, 2009

Keywords

  • Peak walking time
  • Absolute claudication distance
  • Claudication onset time
  • Initial claudication distance
  • Intermittent compression

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by FlowMedic on 2009-12-17.